HBK Investments’s CytomX Therapeutics CTMX Stock Holding History

HBK Investments’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-49,400	Closed	-$914K	–	1234
2018 Q3	$914K	Buy	+49,400	New	+$1.13M	0.01%	754

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

HBK Investments's CTMX Position: Q4 2018 in Review

HBK Investments sold out of CytomX Therapeutics (CTMX) in Q4 2018, closing a stake of 49,400 shares — an estimated $914K sold.

HBK Investments first reported a position in CTMX in Q3 2018 and held it in 1 quarter. The position peaked at $914K in Q3 2018. 111 funds tracked by Wall St. Rank hold CTMX as of Q4 2018.

HBK Investments reported no remaining CytomX Therapeutics position as of Q4 2018 after selling out during the quarter.
HBK Investments sold 49,400 CytomX Therapeutics shares in Q4 2018, an estimated $914K.
HBK Investments first reported a position in CytomX Therapeutics in Q3 2018 and held it in 1 quarter.
HBK Investments's CytomX Therapeutics position peaked at $914K in Q3 2018.
111 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2018.

Based on HBK Investments's 13F filing for Q4 2018, filed 14 Feb 2019.